Pharmacological Inhibition of Sclerostin Protects From Breast Cancer-induced Osteolytic Disease and Muscle Weakness

被引：0
|
作者：
Hesse, Eric [1 ]
Schroeder, Saskia [1 ]
Zarecneva, Diana [1 ]
Pamperin, Jenny [1 ]
Saito, Hiroaki [1 ]
Taipaleenmaeki, Hanna [1 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Trauma Hand & Reconstruct Surg, Mol Skeletal Biol Lab, Hamburg, Germany
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2018年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI-0193
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [1] Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness
    Hesse, Eric
    Schroeder, Saskia
    Brandt, Diana
    Pamperin, Jenny
    Saito, Hiroaki
    Taipaleenmaeki, Hanna
    JCI INSIGHT, 2019, 4 (09)
  • [2] Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis
    Silvia Marino
    Ryan T. Bishop
    Patrick Mollat
    Aymen I. Idris
    Calcified Tissue International, 2018, 103 : 206 - 216
  • [3] Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis
    Marino, Silvia
    Bishop, Ryan T.
    Mollat, Patrick
    Idris, Aymen I.
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (02) : 206 - 216
  • [4] Pharmacological Strategies in Lung Cancer-Induced Cachexia: Effects on Muscle Proteolysis, Autophagy, Structure, and Weakness
    Chacon-Cabrera, Alba
    Fermoselle, Clara
    Urtreger, Alejandro J.
    Mateu-Jimenez, Merce
    Diament, Miriam J.
    de Kier Joffe, Elisa D. Bal
    Sandri, Marco
    Barreiro, Esther
    JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (11) : 1660 - 1672
  • [5] Sclerostin: a possible target for the management of cancer-induced bone disease
    Gkotzamanidou, Maria
    Dimopoulos, Meletios A.
    Kastritis, Efstathios
    Christoulas, Dimitrios
    Moulopoulos, Lia A.
    Terpos, Evangelos
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (08) : 761 - 769
  • [6] Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease
    Michelle M. McDonald
    Jesus Delgado-Calle
    Current Osteoporosis Reports, 2017, 15 : 532 - 541
  • [7] Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease
    McDonald, Michelle M.
    Delgado-Calle, Jesus
    CURRENT OSTEOPOROSIS REPORTS, 2017, 15 (06) : 532 - 541
  • [8] Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate
    Pore, Subrata K.
    Hahm, Eun-Ryeong
    Latoche, Joseph D.
    Anderson, Carolyn J.
    Shuai, Yongli
    Singh, Shivendra V.
    CARCINOGENESIS, 2018, 39 (02) : 134 - 145
  • [9] Sulforaphane is a novel inhibitor of breast cancer-induced osteolytic bone resorption
    Pore, Subrata K.
    Latoche, Joseph D.
    Anderson, Carolyn J.
    Adamik, Juraj
    Galson, Deborah L.
    Weiss, Kurt R.
    Lee, Boeun
    Watters, Rebecca J.
    Kumta, Prashant N.
    Singh, Shivendra V.
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Osteolytic Breast cancer causes skeletal Muscle Weakness in an immunocompetent syngeneic Mouse Model
    Regan, Jenna N.
    Mikesell, Carter
    Reiken, Steven
    Xu, Haifang
    Marks, Andrew R.
    Mohammad, Khalid S.
    Guise, Theresa A.
    Waning, David L.
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
12345